SynthesisEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2005
Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis.
Synthesis in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03641131 (A Retrospective, Post-Marketing, Sentinel-based Active Surveillance Study to Evaluate the Safety of Ampholipad Using Real-World Data in Taiwan), which is not on this map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Retrospective, Post-Marketing, Sentinel-based Active Surveillance Study to Evaluate the Safety of Ampholipad Using Real-World Data in Taiwan
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- continuous versus conventional infusion of amphotericin B deoxycholate: a meta-analysis.PloS one · 2013Pooled it
- A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2012Guideline
- Suboptimal antimicrobial stewardship in the COVID-19 era: is humanity staring at a postantibiotic future?Future microbiology · 2021Article
- Adverse effects of amphotericin B in children; a retrospective comparison of conventional and liposomal formulations.British journal of clinical pharmacology · 2018Article
- Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Infection · 2017Review
- Clinical Manifestations and Treatment of Blastomycosis.Clinics in chest medicine · 2017Review
- Drug strategies targeting CYP51 in neglected tropical diseases.Chemical reviews · 2014Review
- Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1).Critical care (London, England) · 2013Review
- Spectrum of fungal infection in a neurology tertiary care center in India.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2012Article
- Section 4: Contrast-induced AKI.Kidney international supplements · 2012Article
- Section 3: Prevention and Treatment of AKI.Kidney international supplements · 2012Article
- A drug utilization evaluation study of amphotericin B in neutropenic patients in a teaching hospital in iran.Iranian journal of pharmaceutical research : IJPR · 2012Article
- Encapsulation and release of Amphotericin B from an ABC triblock fluorous copolymer.Pharmaceutical research · 2012Article
- The role of second-generation antifungal triazoles for treatment of the endemic mycoses.Current infectious disease reports · 2010Article
- Need for quality improvement in renal systematic reviews.Clinical journal of the American Society of Nephrology : CJASN · 2008Article
- A review of clinical experience with newer antifungals in children.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2008Article
- Acetazolamide prevents vacuolar myopathy in skeletal muscle of K(+) -depleted rats.British journal of pharmacology · 2008Article
- [Kala azar. Rare import and significant differential diagnosis].Der Internist · 2006Review
- Corneal Perforation as a Complication of Fungal Interface Infectious Keratitis after Deep Anterior Lamellar Keratoplasty.Middle East African journal of ophthalmologyArticle
- Limonene synergistically augments fluconazole susceptibility in clinicalNational journal of maxillofacial surgeryArticle
Corrections and comments
- Republished as
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amphotericin B is the main therapeutic agent for the treatment of invasive fungal infections; however, it is associated with significant toxicities that limit its use. Other systemic antifungal agents have been developed to improve tolerability while maintaining the efficacy profile of conventional amphotericin B. Fifty-four studies involving 9,228 patients were assessed for the frequency of adverse effects of the main systemic antifungal agents. While the results suggest that liposomal amphotericin B (L-AmB) is the least nephrotoxic of the lipid formulations (14.6%), that conventional amphotericin B (AmB) is the most nephrotoxic (33.2%), and that itraconazole is the most hepatotoxic (31.5%), the lack of standard definitions of antifungal-related adverse effects limits the validity of these results. Furthermore, heterogeneous patient pools and differing protocols make it difficult to draw direct comparisons between studies. With the advent of newer classes of systemic antifungal agents, future trials should conform to definitions that are universally applicable and clinically relevant to allow for such comparisons and to enable evidence-based decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.